Company profile
Apnimed, Inc.
NASDAQ: APMD · Healthcare · Biotechnology
#1 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ —GM —SS 46
v0.1 · 5/100 weight · pillars only
↑ market scale, workforce scale · ↓ listing tenure, filing timeliness
Methodology →Revenue TTM
—
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
—
Employees
65
as of 2026-09-01
Market cap
$1.0B
as of 2026-09-01
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
No filed financials — private or non-XBRL filer.
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Apnimed, Inc.’s financial profile?
Apnimed, Inc. has no structured financials on file — private or non-XBRL filer.
Peers · Healthcare
Corvus Pharmaceuticals, Inc.——Replimune Group, Inc.——Alto Neuroscience, Inc.——Attovia Therapeutics, Inc.——Faeth Therapeutics, Inc.——Olema Pharmaceuticals, Inc.——Neighbors
Middlesex →Key facts
CEOKevin R. Lind
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: APMD
Employees65
IPO date2026-07-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.